Arcis Biotechnology Ltd.. (7/16/19). "Press Release: Arcis Biotechnology and Mirnax Biosens Sign Exclusive License Agreement for Arcis Sample Prep Technology". Daresbury & Madrid.

	Organisation	Arcis Biotechnology Ltd.
	Group	Arcis:Altos (Group)
	Organisation 2	Mirnax Biosens S.L.
	Group	Canaan Research & Investment
	Product	microRNA test (clinical diagnostics)
	Product 2	liquid biopsy
	Person	Odgaard, Katie (Zyme Communications 201108 Senior Account Manager before College Hill Life Sciences)

Enables stabilisation of microRNA biomarkers for early disease diagnosis

Arcis Biotechnology (“Arcis”), the nucleic acid sample preparation solution provider, and Mirnax Biosens (“Mirnax”), the developer of microRNA (miRNA) biomarkers for clinical diagnostics, today announced they have signed an exclusive license agreement for use of Arcis sample preparation and preservation technology.

Under the terms of the agreement, Mirnax gains access to Arcis’ nucleic acid sample preparation and preservation technology, to improve the stability of its clinically validated miRNA biomarkers for early disease detection. Arcis will also work with Mirnax to develop a microfluidic device integrating both technologies.

Mirnax’ biomarkers are designed for early disease diagnosis, including cancer, arthritis, and kidney disease. However, miRNA is often difficult to preserve, degrading rapidly following extraction, which will affect the accuracy of diagnosis. Arcis’ two-step, rapid nucleic acid extraction and preservation technology enables the fragile miRNA biomarkers to be extracted and stabilised in less than three minutes, without the need for instrumentation or heating or cooling steps.

Dr Jan Rogers, Chief Scientific Officer, Arcis Biotechnology, commented: “We are excited to partner with Mirnax, combining our synergistic technologies to improve the accuracy and speed of disease diagnoses. This latest agreement demonstrates the wide breadth of applications for our nucleic acid sample preparation technology, including clinical diagnostics which is an area that we look forward to exploring further.”

Enrique Sainz Martinez, Chief Executive Officer, Mirnax Biosens, said: “Using the Arcis sample prep technology we are able to successfully generate stable biomarkers for the diagnosis of pathologies with high incidence in the current population. This agreement supports our mission to develop products with high clinical value, and to ultimately improve patient quality of life.”

ENDS

Notes to editors

Dr Jan Rogers, Chief Scientific Officer, Arcis Biotechnology
For a high-resolution image please contact Zyme Communications

Media contact:

Katie Odgaard
Zyme Communications
Tel: +44(0) 7787 502 947
Email: katie.odgaard@zymecommunications.com

About Arcis Biotechnology (www.arcisbio.com)

Based at Sci-Tech Daresbury, one of the UK’s premier science parks, Arcis Biotechnology is focused on providing fast and convenient nucleic acid sample prep solutions. Obtaining genetic material from biological samples is a critical step which is often a time consuming and inefficient process. In less than three minutes, and with no prior sample preparation, the Arcis Sample Prep range of products allow users to quickly and conveniently go from cellular material to downstream nucleic acid investigation without the need for traditional isolation or purification. The process requires no laboratory equipment, and as little as 30µl of sample as starting material.

The Arcis technology, including two CE marked in vitro diagnostic products, can be used on many different samples containing DNA and RNA, including whole blood, plasma, urine, buccal swabs, and soil and plant extracts, and is particularly effective at isolating pathogens for detection.

About Mirnax Biosens (http://en.mirnaxbiosens.com/)

Mirnax Biosens, S.L. (Mirnax) is a biotechnology company owned by Canaan Research & Investment, focused on the development of new disruptive technologies based on liquid biopsy, for clinical diagnosis and prognosis.

Mirnax is developing a universal and innovative platform for the validation of genetic biomarkers of different biological nature (DNA, RNA, miRNAs, lncRNA, etc.) to market a technology, based on microqPCR, that can give a personalized diagnostic and prognostic response in a fast and effective way.

This new Mirnax technology gives rise to the development of different diagnostic and prognostic kits that are unique and innovative in the current market and generate a personalized response to each patient.

Our company owns several biomarker panels with clinical value and excellent commercial perspectives. They allow the development of kits for pathologies with high incidence in the current population and for which there are no diagnosis and prognosis options.

Among them, there is a panel of biomarkers for the early diagnosis of Acute Kidney Injury in the early stages, which has been developed in collaboration with IRYCIS; a biomarker to know the response to treatment in patients with Rheumatoid Arthritis, developed with the IMIBIC and a biomarker to diagnose asthma, developed in collaboration with the Jiménez Díaz Foundation.

In addition, the company has developed, in collaboration with Complutense University of Madrid, an automated detection device (electrochemical biosensor), with which several blood biomarkers have been validated for diseases such as cancer, cardiomyopathies, rheumatoid arthritis, asthma, kidney injury or liver failure, as well as another series of biomarkers to detect oral cancer (mouth, lips, tongue or salivary glands cancer) directly from a saliva sample.

Record changed: 2023-06-05

Picture Berlin Partner Top News CareSyntax Raises $61m for Bio Cheese 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]